UK-based Medtech startup Amber Therapeutics has announced the successful closing of its series A financing round, securing $100 million to advance Amber-UI, a breakthrough therapy for women suffering from mixed urinary incontinence (MUI). The financing, which is one of Europe’s series A rounds for a medical technology company, featured participation from leading healthcare and tech Amber Therapeutics will use the latest investment to advance pivotal clinical studies of Amber-UI for FDA approval.
read more..